VAY 736

Drug Profile

VAY 736

Alternative Names: NOV-5; VAY-736

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MorphoSys; Novartis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action B-cell activation factor receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 22 Nov 2016 Novartis completes a phase II trial in Multiple sclerosis in USA, Ukraine, Poland and Czech Republic (NCT02038049)
  • 11 Nov 2016 Efficacy, pharmacodynamics and adverse events data from a phase II trial in Sjogren's syndrome presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 09 Nov 2016 Novartis Pharmaceuticals plans a phase II trial for Sjogren's syndrome in USA, France, Germany and United Kingdom (Parenteral) (NCT02962895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top